Tags

Type your tag names separated by a space and hit enter

Magnesium in CKD: more than a calcification inhibitor?
J Nephrol 2015; 28(3):269-77JN

Abstract

Magnesium fulfils important roles in multiple physiological processes. Accordingly, a tight regulation of magnesium homeostasis is essential. Dysregulated magnesium serum levels, in particular hypomagnesaemia, are common in patients with chronic kidney disease (CKD) and have been associated with poor clinical outcomes. In cell culture studies as well as in clinical situations magnesium levels were associated with vascular calcification, cardiovascular disease and altered bone-mineral metabolism. Magnesium has also been linked to diseases such as metabolic syndrome, diabetes, hypertension, fatigue and depression, all of which are common in CKD. The present review summarizes and discusses the latest clinical data on the impact of magnesium and possible effects of higher levels on the health status of patients with CKD, including an outlook on the use of magnesium-based phosphate-binding agents in this context.

Links

  • PMC Free PDF
    • Publisher Full Text
    ncbi.nlm.nih.gov
    dx.doi.org

    Authors+Show Affiliations

    Floege J
    Division of Nephrology and Clinical Immunology, RWTH University of Aachen, Pauwelsstr. 30, 52057, Aachen, Germany, juergen.floege@rwth-aachen.de.

    MeSH

    AnimalsBone and BonesComorbidityDepressionDiabetes MellitusDietary SupplementsFatigueHealth StatusHumansHypertensionKidneyMagnesiumRenal Insufficiency, ChronicRisk FactorsVascular Calcification

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    25227765

    Citation

    Floege, Jürgen. "Magnesium in CKD: More Than a Calcification Inhibitor?" Journal of Nephrology, vol. 28, no. 3, 2015, pp. 269-77.
    Floege J. Magnesium in CKD: more than a calcification inhibitor? J Nephrol. 2015;28(3):269-77.
    Floege, J. (2015). Magnesium in CKD: more than a calcification inhibitor? Journal of Nephrology, 28(3), pp. 269-77. doi:10.1007/s40620-014-0140-6.
    Floege J. Magnesium in CKD: More Than a Calcification Inhibitor. J Nephrol. 2015;28(3):269-77. PubMed PMID: 25227765.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Magnesium in CKD: more than a calcification inhibitor? A1 - Floege,Jürgen, Y1 - 2014/09/17/ PY - 2014/07/22/received PY - 2014/09/02/accepted PY - 2014/9/18/entrez PY - 2014/9/18/pubmed PY - 2016/2/18/medline SP - 269 EP - 77 JF - Journal of nephrology JO - J. Nephrol. VL - 28 IS - 3 N2 - Magnesium fulfils important roles in multiple physiological processes. Accordingly, a tight regulation of magnesium homeostasis is essential. Dysregulated magnesium serum levels, in particular hypomagnesaemia, are common in patients with chronic kidney disease (CKD) and have been associated with poor clinical outcomes. In cell culture studies as well as in clinical situations magnesium levels were associated with vascular calcification, cardiovascular disease and altered bone-mineral metabolism. Magnesium has also been linked to diseases such as metabolic syndrome, diabetes, hypertension, fatigue and depression, all of which are common in CKD. The present review summarizes and discusses the latest clinical data on the impact of magnesium and possible effects of higher levels on the health status of patients with CKD, including an outlook on the use of magnesium-based phosphate-binding agents in this context. SN - 1724-6059 UR - https://www.unboundmedicine.com/medline/citation/25227765/full_citation L2 - https://dx.doi.org/10.1007/s40620-014-0140-6 DB - PRIME DP - Unbound Medicine ER -